Benefit of Romiplostim vs. Standard of Care (SOC) and SOC+Rituximab in Patients with Immune Thrombocytopenia
Jeffrey Wasser, MD, from the Department of Medicine, Division of Hematology-Oncology, University of Connecticut School of Medicine, Farmington, and colleagues report at the 53rd American Society of Hematology Annual Meeting and Exposition that romiplostim may have greater effects on platelet responses than standard of care (SOC) + rituximab or SOC alone in immune thrombocytopenia (ITP).
Effective Response Rates of Lenalidomide and Rituximab as Initial Treatment of Chronic Lymphocytic Leukemia
Investigators at the 53rd American Society of Hematology Annual Meeting and Exposition presented study data demonstrating high response rates of lenalidomide and rituximab for the initial treatment of chronic lymphocytic leukemia (CLL).
Alemtuzumab Plus Fludarabine and Cyclophosphamide More Effective in High-Risk Chronic Lymphocytic Leukemia
Low-dose alemtuzumab in combination with fludarabine and cyclophosphamide (FCA) induced a higher rate and higher quality of complete remission (CR) than fludarabine and cyclophosphamide (FC) alone in a high-risk chronic lymphocytic leukemia (CLL) population, analysis of the HOVON68 trial presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology concluded.
Overall Survival Not Improved by Lintuzumab + Low-Dose Cytarabine in Older Patients with Untreated AML
Combination therapy of lintuzumab and low-dose cytarabine did not improve overall survival (OS) in older patients with untreated acute myeloid leukemia (AML) when compared with placebo and low-dose cytarabine, according to study results presented at the American Society of Hematology's 53rd Annual Meeting and Exposition.
Minimal maternal complications and fetal detriment were observed in pregnant patients with Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL) who received standard chemotherapy (without anti-metabolites) during their 2nd and 3rd trimesters, according to data from one of the largest studies conducted in this patient group. These results were presented at the American Society of Hematology's 53rd Annual Meeting and Exposition.
Ruxolitinib demonstrated a significant reduction in spleen volume (SV) and improvements in myelofibrosis (MF)-related symptoms in the COMFORT-I study, reported upon at the American Society of Hematology 53rd Annual Meeting and Exposition.
In patients with low or intermediate-1 (int-1) risk myelodysplastic syndrome (MDS) and thrombocytopenia, use of the thrombopoietin (TPO)-receptor agonist, romiplostim, resulted in a 15-fold increase in platelet response as defined by the International Working Group's (IWG) 2006 criteria for hematologic improvement-platelets (HI-P). The data from this randomized, double-blind, placebo-controlled study was presented at the 53rd American Society of Hematology Annual Meeting and Exposition.
Alisertib, an ATP-competitive, orally available inhibitor of aurora A kinase (AAK), was well-tolerated, with responses observed in heavily pretreated patients with aggressive non-Hodgkin's lymphoma (NHL), including after autologous stem cell transplantation (ASCT), noted study investigators at the 53rd Annual Meeting and Exposition of American Society and Hematology.
Fractionated 90Y-Ibritumomab Tiuxetan Effective as First-Line Therapy for Relapsed Follicular Lymphoma
Clinical findings presented at the American Society of Hematology's 53rd Annual Meeting and Exposition demonstrated fractionated radioimmunotherapy (RIT) using 90Y-ibritumomab tiuxetan to be effective as initial chemotherapy of advanced-stage follicular lymphoma (FL) in patients with high tumor burden. Dr. Timothy M. Illidge, MD, PhD, of the School of Cancer and Enabling Sciences, University of Manchester, Manchester, UK and colleagues conducted an international, multicenter Phase 2 trial to evaluate the efficacy and toxicity of fractionated 90Y-ibritumomab tiuxetan RIT as a first-line treatment of relapsed FL.
Excellent PFS and OS Observed with CHOP Combination Regimens in Newly Diagnosed Advanced Stage Follicular Non-Hodgkin's Lymphoma
"In patients with previously untreated, advanced follicular lymphomas (FL)," Joseph Oliver W. Press, MD, PhD, of Fred Hutchinson Cancer Research Center, Seattle, WA, states, "CHOP chemotherapy plus rituximab or CHOP chemotherapy plus 131iodine-tositumomab have produced outstanding progression-free survival (PFS) and overall survival (OS) rates." Dr. Press presented the findings from SWOG-0016, a Phase 3, randomized, intergroup trial at the 53rd American Society of Hematology Meeting and Exposition.
Combining the hyperCVAD regimen with dasatinib, a dual Scr and BCR-ABL kinase inhibitor, is effective in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) or chronic myeloid leukemia in the lymphoid blast phase (CML-LB), according to investigators at the 53rd American Society of Hematology Annual Meeting and Exposition.
Rituximab and Liposomal Doxorubicin Improve Progression-Free and Overall Survival When Added to Chemotherapy in Untreated Burkitt's Lymphoma
At the 53rd American Society of Hematology Annual Meeting and Exposition, study investigators presented evidence demonstrating promising survival rates in Burkitt's lymphoma (BL) when rituximab was added to the CODOX-M and IVAC chemotherapy regimens and when liposomal doxorubicin was used in place of doxorubicin in the CODOX-M regimen.
CLAG in Combination with Imatinib Mesylate Shows Promise in Relapsed or Refractory Acute Myeloid Leukemia
Rami S. Komrokji, MD, from H. Lee Moffitt Cancer Center & Research Institute in Tampa, FL, and colleagues reported study data indicating that the CLAG regimen (cladribine, cytarabine, granulocyte colony stimulating factor) in combination with imatinib mesylate showed encouraging signs of activity in relapsed or refractory (RR) acute myeloid leukemia (AML). Results of this single-institution, two-stage, Phase 2 study were presented at the 53rd American Society of Hematology Annual Meeting and Exposition.
R-BAC Effective In Patients With Mantle Cell Lymphoma Not Eligible for Intensive Chemotherapy or Autologous Transplant
The rituximab, bendamustine and cytarabine (R-BAC) chemotherapy regimen was shown to be effective in previously untreated patients >65 years old with mantle cell lymphoma (MCL), as well as in patients who are relapsed or refractory (R/R) to one previous line of immunochemotherapy, based on results of a prospective Phase 2 study presented at the 53rd American Society of Hematology Annual Meeting and Exposition.
Therapeutic Potential of Bafetinib Observed in Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
At the 53rd American Society of Hematology Annual Meeting and Exposition, study investigators presented data showing that bafetinib has therapeutic potential in the treatment of patients with B-cell chronic lymphocytic leukemia (B-CLL) who relapsed or were refractory to >1 course of treatment with either an alkylating agent, rituximab, or a fludarabine-based regimen.
In children with newly diagnosed acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS), no significant differences in efficacy or toxicity were observed between idarubicin and mitoxantrone induction and first intensification courses, results of a randomized, Phase 3 study presented at the 53rd American Society of Hematology Annual Meeting and Exposition has found.
Resminostat Has Potential to Offer Substantial Clinical Benefit to Patients with Relapsed or Refractory Hodgkin's Lymphoma
At the 53rd American Society of Hematology Annual Meeting and Exposition, study investigators presented data from the SAPHIRE trial demonstrating that resminostat, an oral pan-histone deacetylase (HDAC) inhibitor, showed considerable anti-tumor activity in a heavily pre-treated population with Hodgkin's Lymphoma.
Romiplostim Enhances Long-Term Platelet Responses in Thrombocytopenic Patients with Myelodysplastic Syndromes
Long-term use of romiplostim in myelodysplastic syndrome (MDS) patients for up to 3.5 years (five years including therapy on prior studies) produced platelet responses in 83% of patients, according to an open-label extension study presented at the 53rd American Society of Hematology Annual Meeting and Exposition.
Standard-dose rituximab plus multiple courses of pulse dexamethasone was shown to be active with manageable toxicity in patients with immune thrombocytopenia (ITP), according to results of a retrospective analysis presented during the 53rd American Society of Hematology Annual Meeting and Exposition.
A retrospective review reported on during the 53rd American Society of Hematology Annual Meeting and Exposition found vinorelbine, paclitaxel, etoposide, cisplatin and cytarabine (VTEPA) to be a promising salvage regimen in patients with relapsed/refractory Hodgkin's lymphoma. However, patients with refractory diffuse large B-cell lymphoma (DLBCL) had "exceedingly poor" outcomes in comparison.
Addition of Bortezomib to Thalidomide-Dexamethasone as Post-ASCT Consolidation Therapy Significantly Increases Response and PFS in Multiple Myeloma
Patients with multiple myeloma (MM) had significantly increased rates of complete response (CR) and progression-free survival (PFS)—including superior PFS across poor prognosis subgroups—when postautologous stem cell transplantation (ASCT) consolidation therapy utilized bortezomib-thalidomide-dexamethasone compared with thalidomide-dexamethasone, investigators reported during the 53rd American Society of Hematology Annual Meeting and Exposition.
A first-line regimen that incorporated gemcitabine with rituximab, cyclophosphamide, vincristine, and prednisolone (R-GCVP) for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) ineligible for anthracycline-containing chemotherapy delivered "excellent overall response rates" in this challenging population, a Phase 2 study presented during the 53rd American Society of Hematology Annual Meeting and Exposition has found.
The first prospective study to assess bortezomib + dexamethasone as second-line treatment in patients with multiple myeloma (MM) found the regimen to be feasible and active, investigators concluded during the 53rd American Society of Hematology Annual Meeting and Exposition. In addition, overall renal function was shown to improve with treatment.
Pixantrone Instead of Doxorubicin in CHOP-R Regimen Has Comparable Efficacy, Reduced Cardiotoxicity in DLBCL
For patients with untreated diffuse large B-cell lymphoma (DLBCL), CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisolone + rituximab) is standard therapy. In a study in which pixantrone dimaleate replaced doxorubicin (CPOP-R), comparable efficacy with reduced cardiotoxicity was observed, investigators reported during the 53rd American Society of Hematology Annual Meeting and Exposition.
Erlotinib Shows Promise in Patients with Myelodysplastic Syndrome Following Azanucleoside Treatment Failure
Erlotinib was found to have an acceptable toxicity profile in patients with myelodysplastic syndromes (MDS) and antileukemic activity in those with poor risk MDS in whom treatment with azanucleoside agents has failed, according to results of a Phase 2 study presented during the 53rd American Society of Hematology Annual Meeting and Exposition.
Prolonged use of tyrosine kinase inhibitors (TKIs) plus chemotherapy and stem cell transplantation (SCT) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), a disease of predominantly older persons, can achieve long-term survival, according to results of a study reported during the 53rd American Society of Hematology Annual Meeting and Exposition.
Fludarabine, Mitoxantrone Plus 90Y-Ibritumomab Tiuxetan Safe, Effective in Treatment-Naive Patients with Follicular Lymphoma
Investigators at the 53rd American Society of Hematology Annual Meeting and Exposition reported that long-term efficacy and toxicity of fludarabine and mitoxantrone followed by radioimmunotherapy with 90Y ibritumomab tiuxetan had six-year rates of progression-free survival (PFS) and overall survival (OS) that compared favorably with chemoimmunotherapy alone in patients with untreated follicular lymphoma (FL).
Pretreatment with Clofarabine-Containing Regimens Does Not Adversely Affect Outcomes in Younger Patients with AML Undergoing Allo-SCT
Pre-transplant chemotherapy regimens that included the purine nucleoside analog clofarabine did not negatively affect outcomes in younger patients with acute myeloid leukemia (AML) who were undergoing allogenic stem cell transplant (allo-SCT) compared with those pretreated with non-clofarabine containing regimens, according to results of a study reported during the 53rd American Society of Hematology Annual Meeting and Exposition.
Oral Lenalidomide May Have Utility as Maintenance Therapy in Patients with Relapsed/Advanced Cutaneous T-Cell Lymphoma
Oral lenalidomide demonstrated activity in patients with relapsed/advanced cutaneous T-cell lymphoma (CTCL) consistent with that of other currently available agents, according to results of a Phase 2 multicenter trial presented at the 53rd American Society of Hematology Annual Meeting and Exposition.
Adult patients with acute lymphocytic leukemia (ALL) and lymphoblastic lymphoma (LL) treated with the Hyper-CVAD regimen are at very high risk for rapid bone loss from the high-dose corticosteroid early in their treatment, the first study to show such a loss concluded during at the 53rd American Society of Hematology Annual Meeting and Exposition.
An open-label study of seven pediatric patients with paroxysmal nocturnal hemoglobinuria (PNH) found short-term infusions of eculizumab to be well tolerated, with reduced intravascular hemolysis. These results, reported during the 53rd American Society of Hematology Annual Meeting and Exposition, were consistent with those found in adults with this disease and suggest the potential for this treatment in children and adolescents with PNH.
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- Refined Equation May Obviate Oncotype DX in Breast Cancer Treatment Decisions
- Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis
- Intermediate Oncotype DX Scores Prognostic of OS in Early-stage Breast Cancer
- Colorectal Cancer and Dietary Fiber: Source Is More Important Than Amount
- Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|